Found: 14
Select item for more details and to access through your institution.
Declines in highly active antiretroviral therapy initiation at CD4 cell counts ≤ 200 cells/μL and the contribution of diagnosis of HIV at CD4 cell counts ≤ 200 cells/μL in British Columbia, Canada.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
Declines in highly active antiretroviral therapy initiation at CD4 cell counts ≤ 200 cells/μL and the contribution of diagnosis of HIV at CD4 cell counts ≤ 200 cells/μL in British Columbia, Canada.
- Published in:
- HIV Medicine, 2015, v. 16, n. 6, p. 337, doi. 10.1111/hiv.12212
- By:
- Publication type:
- Article
THE OUTCOME OF GLOFITAMAB THERAPY IN PATIENTS WITH AGGRESSIVE REFRACTORY B‐NHL IN REAL CLINICAL PRACTICE.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 715, doi. 10.1002/hon.3165_569
- By:
- Publication type:
- Article
BRENTUXIMAB VEDOTIN FOR TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN A REAL WORLD SETTING: CLINICAL OUTCOMES AND IMPACT ON QUALITY OF LIFE.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.67_2881
- By:
- Publication type:
- Article
INFECTIOUS COMPLICATIONS OF NIVOLUMAB THERAPY IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 502, doi. 10.1002/hon.184_2631
- By:
- Publication type:
- Article
CASE SERIES OF NIVOLUMAB TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY HIV‐RELATED LYMPHOMAS.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 500, doi. 10.1002/hon.183_2631
- By:
- Publication type:
- Article
RETREATMENT WITH NIVOLUMAB IN PATIENTS WITH R/R CLASSICAL HODGKIN LYMPHOMA AFTER DISCONTINUATION OF THE THERAPY WITH IMMUNE CHECKPOINT INHIBITORS.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 496, doi. 10.1002/hon.176_2631
- By:
- Publication type:
- Article
RESPONSE TO NIVOLUMAB AS ≥3<sup>rd</sup> LINE THERAPY IN PTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA (CHL) AND ITS IMPACT ON QUALITY OF LIFE IN RESPONDERS AND NONRESPONDERS.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 495, doi. 10.1002/hon.174_2631
- By:
- Publication type:
- Article
TREATMENT OF RELAPSED AND REFRACTORY T‐CELL LYMPHOMAS: FIRST PAVLOV STATE MEDICAL UNIVERSITY OF SAINT‐PETERSBURG EXPERIENCE.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 473, doi. 10.1002/hon.152_2631
- By:
- Publication type:
- Article
INFECTIOUS COMPLICATIONS OF NIVOLUMAB THERAPY IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 502, doi. 10.1002/hon.184_2631
- By:
- Publication type:
- Article
CASE SERIES OF NIVOLUMAB TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY HIV‐RELATED LYMPHOMAS.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 500, doi. 10.1002/hon.183_2631
- By:
- Publication type:
- Article
RETREATMENT WITH NIVOLUMAB IN PATIENTS WITH R/R CLASSICAL HODGKIN LYMPHOMA AFTER DISCONTINUATION OF THE THERAPY WITH IMMUNE CHECKPOINT INHIBITORS.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 496, doi. 10.1002/hon.176_2631
- By:
- Publication type:
- Article
RESPONSE TO NIVOLUMAB AS ≥3<sup>rd</sup> LINE THERAPY IN PTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA (CHL) AND ITS IMPACT ON QUALITY OF LIFE IN RESPONDERS AND NONRESPONDERS.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 495, doi. 10.1002/hon.174_2631
- By:
- Publication type:
- Article
TREATMENT OF RELAPSED AND REFRACTORY T‐CELL LYMPHOMAS: FIRST PAVLOV STATE MEDICAL UNIVERSITY OF SAINT‐PETERSBURG EXPERIENCE.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 473, doi. 10.1002/hon.152_2631
- By:
- Publication type:
- Article